In a study by Tang et al., comparing new users of SGLT2 inhibitors with those initiating sulfonylureas, a significantly lower risk of all-cause dementia was reported (risk difference: -2.5%; 95% CI: -3.0% to -2.1%) [9]. This evidence concerns the gene SLC5A2 and dementia.